Search

Your search keyword '"Perings, Christian A."' showing total 334 results
Start Over Author "Perings, Christian A."
334 results on '"Perings, Christian A."'

55. Single beta-blocker or combined amiodarone therapy in implantable cardioverter-defibrillator and cardiac resynchronization therapy—defibrillator patients: Insights from the German DEVICE registry

Author

Wiedmann, Felix, primary, Ince, Hüseyin, additional, Stellbrink, Christoph, additional, Kleemann, Thomas, additional, Eckardt, Lars, additional, Brachmann, Johannes, additional, Gonska, Bernd-Dieter, additional, Kääb, Stefan, additional, Perings, Christian A., additional, Jung, Werner, additional, Lugenbiel, Patrick, additional, Hochadel, Matthias, additional, Senges, Jochen, additional, Frey, Norbert, additional, and Schmidt, Constanze, additional

Published
2022
Full Text
View/download PDF

59. The wearable cardioverter-defibrillator: current technology and evolving indications

Author

Reek, Sven, Burri, Haran, Roberts, Paul R., Perings, Christian, Epstein, Andrew E., Klein, Helmut U., Lip, Gregory, Gorenek, Bulent, Sticherling, Christian, Fauchier, Laurent, Goette, Andreas, Jung, Werner, Vos, Marc A., Brignole, Michele, Elsner, Christian, Dan, Gheorghe-Andrei, Marin, Francisco, Boriani, Giuseppe, Lane, Deirdre, Lundqvist, Carina Blomstrom, and Savelieva, Irina

Published
2017
Full Text
View/download PDF

60. Structural components for the development of a heart failure network.

Author

Luedike, Peter, Papathanasiou, Maria, Schmack, Bastian, Kamler, Markus, Perings, Christian, Ruhparwar, Arjang, and Rassaf, Tienush

Subjects
MEDICAL personnel, CARDIOLOGISTS, HEART failure, HEALTH facilities, STRUCTURAL components, REGIONAL development
Abstract

Diagnosis and treatment of heart failure (HF) is challenging, and development of specialized HF networks is mandatory to warrant broad access to guideline directed therapies for patients. Numerous national cardiovascular societies recommend a three‐level association of health care providers. This comprises tertiary academic centres, specialized HF clinics and specialized general cardiologists to cover the large spectrum of HF severity and entities. Although this idea of a multi‐level care is widely accepted, optimal approach to build and implement a HF network service needs further definition. The core principle is that of network healthcare facilities that also consider regional peculiarities and that implements academic standards, quality indicators (QIs), interdisciplinarity and reimbursement strategies. These determinants of trans‐sectoral healthcare need to be embedded in a network that provides sustainability and that incorporates QIs to objectify the efficacy of specific measures. The basis of a HF‐network should be a certification system of the respective national HF association to warrant guideline standards and to prevent development of regional hierarchies or dependencies between members. This nationwide framework needs to be complemented by a federal system of regional networks, which also takes local demands into account. These regional units should incorporate digital communication and interaction pathways, structured educational programmes, certified telehealth concepts and follow‐up algorithms to meet the requirements of sustainability and efficacy. We here summarize different components of HF networks and introduce the structure and development philosophy of the RUHR‐HF‐network that constitutes the first certified HF‐clinics‐network in the Ruhr area—the largest metropolitan area in Germany. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

61. Intramyocardial Inflammation after COVID-19 Vaccination: An Endomyocardial Biopsy-Proven Case Series

Author

Baumeier, Christian, primary, Aleshcheva, Ganna, additional, Harms, Dominik, additional, Gross, Ulrich, additional, Hamm, Christian, additional, Assmus, Birgit, additional, Westenfeld, Ralf, additional, Kelm, Malte, additional, Rammos, Spyros, additional, Wenzel, Philip, additional, Münzel, Thomas, additional, Elsässer, Albrecht, additional, Gailani, Mudather, additional, Perings, Christian, additional, Bourakkadi, Alae, additional, Flesch, Markus, additional, Kempf, Tibor, additional, Bauersachs, Johann, additional, Escher, Felicitas, additional, and Schultheiss, Heinz-Peter, additional

Published
2022
Full Text
View/download PDF

64. Structural components for the development of a heart failure network

Author

Lüdike, Peter, Papathanasiou, Maria, Schmack, Bastian, Kamler, Markus, Perings, Christian, Ruhparwar, Arjang, and Rassaf, Tienush

Subjects
Medizin
Abstract

Diagnosis and treatment of heart failure (HF) is challenging, and development of specialized HF networks is mandatory to warrant broad access to guideline directed therapies for patients. Numerous national cardiovascular societies recommend a three-level association of health care providers. This comprises tertiary academic centres, specialized HF clinics and specialized general cardiologists to cover the large spectrum of HF severity and entities. Although this idea of a multi-level care is widely accepted, optimal approach to build and implement a HF network service needs further definition. The core principle is that of network healthcare facilities that also consider regional peculiarities and that implements academic standards, quality indicators (QIs), interdisciplinarity and reimbursement strategies. These determinants of trans-sectoral healthcare need to be embedded in a network that provides sustainability and that incorporates QIs to objectify the efficacy of specific measures. The basis of a HF-network should be a certification system of the respective national HF association to warrant guideline standards and to prevent development of regional hierarchies or dependencies between members. This nationwide framework needs to be complemented by a federal system of regional networks, which also takes local demands into account. These regional units should incorporate digital communication and interaction pathways, structured educational programmes, certified telehealth concepts and follow-up algorithms to meet the requirements of sustainability and efficacy. We here summarize different components of HF networks and introduce the structure and development philosophy of the RUHR-HF-network that constitutes the first certified HF-clinics-network in the Ruhr area—the largest metropolitan area in Germany. OA Förderung 2022

Published
2022

66. Transfemoral aortic valve implantation: procedural hospital volume and mortality in Germany.

Author

Bestehorn, Kurt, Bestehorn, Maike, Zahn, Ralf, Perings, Christian, Stellbrink, Christoph, and Schächinger, Volker

Subjects
HOSPITAL mortality, AORTIC valve, HEART valve prosthesis implantation
Abstract

Aims Studies assessing transfemoral transcatheter aortic valve implantation (TF-TAVI) showed lower rates of in-hospital mortality at high-volume hospitals and minimum caseloads were recommended to assure quality standards. Methods and results All patients in the German mandatory quality assurance registry with elective or urgent TF-TAVI procedures in 2018 and 2019 at 81 and 82 hospitals, respectively, were analysed. Observed in-hospital mortality was adjusted to expected mortality by the German AKL-KATH score (O/E) as well as by the EuroScore II (O/E2). Hospital volume and O/E were correlated by regression analyses and volume quartiles. 18 763 patients (age: 81.1 ± 1.0 years, mean EuroSCORE II: 6.9 ± 1.8%) and 22 137 patients (mean age: 80.7 ± 3.5 years, mean EuroSCORE II: 6.5 ± 1.6%) were analysed in 2018 and 2019, respectively. The average observed in-hospital mortality was 2.57 ± 1.83% and 2.36 ± 1.60%, respectively. Unadjusted in-hospital mortality was significantly inversely related to hospital volume by linear regression in both years. After risk adjustment, the association between hospital volume and O/E was statistically significant in 2019 (R 2 = 0.049; P = 0.046), but not in 2018 (R 2 = 0.027; P = 0.14). The variance of O/E explained by the number of cases in 2019 was low (4.9%). Differences in O/E outcome between the first and the fourth quartile were not statistically significant in both years (1.10 ± 1.02 vs. 0.82 ± 0.46; P = 0.26 in 2018; 1.16 0.97 vs. 0.74 ± 0.39; P = 0.084 in 2019). Any chosen volume cut-off could not precisely differentiate between hospitals with not acceptable quality (>95th percentile O/E of all hospitals) and those with acceptable (O/E ≤95th percentile) or above-average (O/E < 1) quality. For example, in 2019 a cut-off value of 150 would only exclude one of two hospitals with not acceptable quality, while 20 hospitals with acceptable or above-average quality (25% of all hospitals) would be excluded. Conclusion The association between hospital volume and in-hospital mortality in patients undergoing elective TF-TAVI in Germany in 2018 and 2019 was weak and not consistent throughout various analytical approaches, indicating no clinical relevance of hospital volume for the outcome. However, these data were derived from a healthcare system with restricted access to hospitals to perform TAVI and overall high TAVI volumes. Instead of the unprecise surrogate hospital volume, the quality of hospitals performing TF-TAVI should be directly assessed by real achieved risk-adjusted mortality. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

78. Pulmonary Hypertension in Adults with Congenital Heart Disease: Real-World Data from the International COMPERA-CHD Registry

Author

Kaemmerer, Harald, Gorenflo, Matthias, Huscher, Dorte, Pittrow, David, Apitz, Christian, Baumgartner, Helmut, Berger, Felix, Bruch, Leonhard, Brunnemer, Eva, Budts, Werner, Claussen, Martin, Coghlan, Gerry, Dahnert, Ingo, D'Alto, Michele, Delcroix, Marion, Distler, Oliver, Dittrich, Sven, Dumitrescu, Daniel, Ewert, Ralf, Faehling, Martin, Germund, Ingo, Ghofrani, Hossein Ardeschir, Grohe, Christian, Grossekreymborg, Karsten, Halank, Michael, Hansmann, Georg, Harzheim, Dominik, Nemes, Attila, Havasi, Kalman, Held, Matthias, Hoeper, Marius M., Hofbeck, Michael, Hohenfrost-Schmidt, Wolfgang, Jureviciene, Elena, Gumbiene, Lina, Kabitz, Hans-Joachim, Klose, Hans, Koehler, Thomas, Konstantinides, Stavros, Koeestenberger, Martin, Kozlik-Feldmann, Rainer, Kramer, Hans-Heiner, Kropf-Sanchen, Cornelia, Lammers, Astrid, Lange, Tobias, Meyn, Philipp, Miera, Oliver, Milger-Kneidinger, Katrin, Neidenbach, Rhoia, Neurohr, Claus, Opitz, Christian, Perings, Christian, Remppis, Bjoern Andrew, Riemekasten, Gabriele, Scelsi, Laura, Scholtz, Werner, Simkova, Iveta, Skowasch, Dirk, Skride, Andris, Staehler, Gerd, Stiller, Brigitte, Tsangaris, Iraklis, Vizza, Carmine Dario, Noordegraaf, Anton Vonk, Wilkens, Heinrike, Wirtz, Hubert, Diller, Gerhard-Paul, Gruenig, Ekkehard, Rosenkranz, Stephan, Kaemmerer, Harald, Gorenflo, Matthias, Huscher, Dorte, Pittrow, David, Apitz, Christian, Baumgartner, Helmut, Berger, Felix, Bruch, Leonhard, Brunnemer, Eva, Budts, Werner, Claussen, Martin, Coghlan, Gerry, Dahnert, Ingo, D'Alto, Michele, Delcroix, Marion, Distler, Oliver, Dittrich, Sven, Dumitrescu, Daniel, Ewert, Ralf, Faehling, Martin, Germund, Ingo, Ghofrani, Hossein Ardeschir, Grohe, Christian, Grossekreymborg, Karsten, Halank, Michael, Hansmann, Georg, Harzheim, Dominik, Nemes, Attila, Havasi, Kalman, Held, Matthias, Hoeper, Marius M., Hofbeck, Michael, Hohenfrost-Schmidt, Wolfgang, Jureviciene, Elena, Gumbiene, Lina, Kabitz, Hans-Joachim, Klose, Hans, Koehler, Thomas, Konstantinides, Stavros, Koeestenberger, Martin, Kozlik-Feldmann, Rainer, Kramer, Hans-Heiner, Kropf-Sanchen, Cornelia, Lammers, Astrid, Lange, Tobias, Meyn, Philipp, Miera, Oliver, Milger-Kneidinger, Katrin, Neidenbach, Rhoia, Neurohr, Claus, Opitz, Christian, Perings, Christian, Remppis, Bjoern Andrew, Riemekasten, Gabriele, Scelsi, Laura, Scholtz, Werner, Simkova, Iveta, Skowasch, Dirk, Skride, Andris, Staehler, Gerd, Stiller, Brigitte, Tsangaris, Iraklis, Vizza, Carmine Dario, Noordegraaf, Anton Vonk, Wilkens, Heinrike, Wirtz, Hubert, Diller, Gerhard-Paul, Gruenig, Ekkehard, and Rosenkranz, Stephan

Abstract

Introduction: Pulmonary hypertension (PH) is a common complication in patients with congenital heart disease (CHD), aggravating the natural, post-operative, or post-interventional course of the underlying anomaly. The various CHDs differ substantially in characteristics, functionality, and clinical outcomes among each other and compared with other diseases with pulmonary hypertension. Objective: To describe current management strategies and outcomes for adults with PH in relation to different types of CHD based on real-world data. Methods and results: COMPERA (Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension) is a prospective, international PH registry comprising, at the time of data analysis, >8200 patients with various forms of PH. Here, we analyzed a subgroup of 680 patients with PH due to CHD, who were included between 2007 and 2018 in 49 specialized centers for PH and/or CHD located in 11 European countries. At enrollment, the patients' median age was 44 years (67% female), and patients had either pre-tricuspid shunts, post-tricuspid shunts, complex CHD, congenital left heart or aortic disease, or miscellaneous other types of CHD. Upon inclusion, targeted therapies for pulmonary arterial hypertension (PAH) included endothelin receptor antagonists, PDE-5 inhibitors, prostacyclin analogues, and soluble guanylate cyclase stimulators. Eighty patients with Eisenmenger syndrome were treatment-naive. While at inclusion the primary PAH treatment for the cohort was monotherapy (70% of patients), with 30% of the patients on combination therapy, after a median observation time of 45.3 months, the number of patients on combination therapy had increased significantly, to 50%. The use of oral anticoagulants or antiplatelets was dependent on the underlying diagnosis or comorbidities. In the entire COMPERA-CHD cohort, after follow-up and receiving targeted PAH therapy (n = 511), 91 patients died over the course of a 5-year follow up. Th

Published
2020

89. Correction to: Protected risk stratification with the wearable cardioverter-defibrillator: results from the WEARIT-II-EUROPE registry

Author

Veltmann, Christian, primary, Winter, Stefan, additional, Duncker, David, additional, Jungbauer, Carsten G., additional, Wäßnig, Nadine K., additional, Geller, J. Christoph, additional, Erath, Julia W., additional, Goeing, Olaf, additional, Perings, Christian, additional, Ulbrich, Michael, additional, Roser, Mattias, additional, Husser, Daniela, additional, Gansera, Laura S., additional, Soezener, Korkut, additional, Malur, Frank Michael, additional, Block, Michael, additional, Fetsch, Thomas, additional, Kutyifa, Valentina, additional, and Klein, Helmut U., additional

Published
2020
Full Text
View/download PDF

90. Pulmonary Hypertension in Adults with Congenital Heart Disease: Real-World Data from the International COMPERA-CHD Registry

Author

Kaemmerer, Harald, primary, Gorenflo, Matthias, additional, Huscher, Dörte, additional, Pittrow, David, additional, Apitz, Christian, additional, Baumgartner, Helmut, additional, Berger, Felix, additional, Bruch, Leonhard, additional, Brunnemer, Eva, additional, Budts, Werner, additional, Claussen, Martin, additional, Coghlan, Gerry, additional, Dähnert, Ingo, additional, D’Alto, Michele, additional, Delcroix, Marion, additional, Distler, Oliver, additional, Dittrich, Sven, additional, Dumitrescu, Daniel, additional, Ewert, Ralf, additional, Faehling, Martin, additional, Germund, Ingo, additional, Ghofrani, Hossein Ardeschir, additional, Grohé, Christian, additional, Grossekreymborg, Karsten, additional, Halank, Michael, additional, Hansmann, Georg, additional, Harzheim, Dominik, additional, Nemes, Attila, additional, Havasi, Kalman, additional, Held, Matthias, additional, M. Hoeper, Marius, additional, Hofbeck, Michael, additional, Hohenfrost-Schmidt, Wolfgang, additional, Jurevičienė, Elena, additional, Gumbienè, Lina, additional, Kabitz, Hans-Joachim, additional, Klose, Hans, additional, Köhler, Thomas, additional, Konstantinides, Stavros, additional, Köestenberger, Martin, additional, Kozlik-Feldmann, Rainer, additional, Kramer, Hans-Heiner, additional, Kropf-Sanchen, Cornelia, additional, Lammers, Astrid, additional, Lange, Tobias, additional, Meyn, Philipp, additional, Miera, Oliver, additional, Milger-Kneidinger, Katrin, additional, Neidenbach, Rhoia, additional, Neurohr, Claus, additional, Opitz, Christian, additional, Perings, Christian, additional, Remppis, Bjoern Andrew, additional, Riemekasten, Gabriele, additional, Scelsi, Laura, additional, Scholtz, Werner, additional, Simkova, Iveta, additional, Skowasch, Dirk, additional, Skride, Andris, additional, Stähler, Gerd, additional, Stiller, Brigitte, additional, Tsangaris, Iraklis, additional, Vizza, Carmine Dario, additional, Vonk Noordegraaf, Anton, additional, Wilkens, Heinrike, additional, Wirtz, Hubert, additional, Diller, Gerhard-Paul, additional, Grünig, Ekkehard, additional, and Rosenkranz, Stephan, additional

Published
2020
Full Text
View/download PDF

91. Protected risk stratification with the wearable cardioverter-defibrillator: results from the WEARIT-II-EUROPE registry

Author

Veltmann, Christian, primary, Winter, Stefan, additional, Duncker, David, additional, Jungbauer, Carsten G., additional, Wäßnig, Nadine K., additional, Geller, J. Christoph, additional, Erath, Julia W., additional, Goeing, Olaf, additional, Perings, Christian, additional, Ulbrich, Michael, additional, Roser, Mattias, additional, Husser, Daniela, additional, Gansera, Laura S., additional, Soezener, Korkut, additional, Malur, Frank Michael, additional, Block, Michael, additional, Fetsch, Thomas, additional, Kutyifa, Valentina, additional, and Klein, Helmut U., additional

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results